This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

CHLA participates in novel cancer consortium announced at the Biden Cancer Summit

September 22nd, 2018
CHLA participates in novel cancer consortium announced at the Biden Cancer Summit
Lee Helman, M.D., head of Basic and Translational Research within the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, is a founding member of the newly formed Pediatric and SDH-Deficient GIST Consortium. Credit: CHLA

Former Vice President Joe Biden and Dr. Jill Biden hosted the national Biden Cancer Summit, on Sept. 21, to highlight the urgent need for creating transformative approaches to cancer prevention, research and treatment. One of the new initiatives announced was the formation of a consortium to advance research into effective treatments for patients with a type of cancer called Gastrointestinal Stromal Tumor (GIST) who do not respond to current standard treatments.

Lee Helman, MD, head of Basic and Translational Research within the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, is a founding member of the newly formed, Pediatric and SDH-Deficient GIST Consortium. In 2008, Helman was responsible for the initiation of the first clinic devoted to pediatric patients with "wild-type GIST" who did not benefit from the treatment that had recently been found effective for most adult GIST patients. The vast majority of the patients who did not respond to treatment were determined to have a genetic mutation and subsequently identified as having SDH-deficient GIST tumors. The initial clinic at NIH was supported by the Life Raft Group.

The Life Raft Group began as a group of patients and caregivers affected by GIST and has expanded to include advocacy, research and patient care. In order to incubate progress for this rare disease population, they now have formed the Pediatric and SDH-Deficient GIST Consortium, with the goal of identifying at least one effective treatment within three years as demonstrated by the initiation of clinical trials for these patients.

The initial focus of the Consortium will include creation of a platform for shared data to answer key questions, establishment of a tissue bank and guidelines for clinical stakeholders, and the generation of cell lines used to advance research. Access and outreach strategies will include training for community oncologists and educational webinars for patients and families worldwide.

Provided by Children's Hospital Los Angeles

Citation: CHLA participates in novel cancer consortium announced at the Biden Cancer Summit (2018, September 22) retrieved 21 September 2025 from https://sciencex.com/wire-news/299049749/chla-participates-in-novel-cancer-consortium-announced-at-the-bi.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.